JP2023525298A5 - - Google Patents

Info

Publication number
JP2023525298A5
JP2023525298A5 JP2022567837A JP2022567837A JP2023525298A5 JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5 JP 2022567837 A JP2022567837 A JP 2022567837A JP 2022567837 A JP2022567837 A JP 2022567837A JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5
Authority
JP
Japan
Prior art keywords
acid sequence
sequence
antibody
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031541 external-priority patent/WO2021226576A1/en
Publication of JP2023525298A publication Critical patent/JP2023525298A/ja
Publication of JP2023525298A5 publication Critical patent/JP2023525298A5/ja
Pending legal-status Critical Current

Links

JP2022567837A 2020-05-08 2021-05-10 Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 Pending JP2023525298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031541 WO2021226576A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023525298A JP2023525298A (ja) 2023-06-15
JP2023525298A5 true JP2023525298A5 (cg-RX-API-DMAC7.html) 2024-05-20

Family

ID=76197640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567837A Pending JP2023525298A (ja) 2020-05-08 2021-05-10 Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用

Country Status (11)

Country Link
US (4) US12503508B2 (cg-RX-API-DMAC7.html)
EP (2) EP4146699A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525298A (cg-RX-API-DMAC7.html)
KR (2) KR20230017793A (cg-RX-API-DMAC7.html)
CN (2) CN115768795A (cg-RX-API-DMAC7.html)
AU (2) AU2021269130A1 (cg-RX-API-DMAC7.html)
CA (2) CA3178038A1 (cg-RX-API-DMAC7.html)
GB (2) GB2613259A (cg-RX-API-DMAC7.html)
IL (2) IL297982A (cg-RX-API-DMAC7.html)
TW (2) TW202208430A (cg-RX-API-DMAC7.html)
WO (2) WO2021226591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
TW202330911A (zh) * 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性t細胞及其製作方法
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202547858A (zh) 2024-04-22 2025-12-16 美商電子療法股份有限公司 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) * 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
CN111511766B (zh) * 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
CR20200566A (es) * 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
MX2021015937A (es) 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.
EP4110819A1 (en) 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
EP4429768A2 (en) 2021-11-10 2024-09-18 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體

Similar Documents

Publication Publication Date Title
US20230242648A1 (en) Antibodies to integrin avb6 and use of same to treat cancer
AU2016276751B2 (en) CD123 antibodies and conjugates thereof
US20210047404A1 (en) Cd33 antibodies and use of same to treat cancer
GB2613259A (en) SIRP alpha and SIRP beta 1 antibodies and uses thereof
WO2019144945A1 (en) Anti-pd-l1 antibody and il-7 fusions
US8545844B2 (en) Humanized antibodies against human IL-22RA
US20230080842A1 (en) Tetravalent symmetric bispecific antibodies
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
JP2024513921A (ja) 抗cd122抗体及びその使用
WO2018117237A1 (ja) 抗cd3抗体及び該抗体を含む分子
JP7843824B2 (ja) 抗体および使用方法
CN119768425A (zh) 抗-tl1a抗体及其使用方法
WO2021262791A1 (en) High affinity antibodies targeting tau phosphorylated at serine 413
JP2023537078A (ja) COVID-19を治療及び防止するためのSARS-CoV-2抗体
WO2021258337A1 (en) Human monoclonal antibodies against tigit for immune related diseases
JP2022527790A5 (cg-RX-API-DMAC7.html)
JPWO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
JP2023525753A5 (cg-RX-API-DMAC7.html)
WO2025103425A1 (en) Multispecific antibodies and uses thereof
WO2024131849A1 (zh) Cd38单克隆抗体及其应用
JP2020507338A (ja) 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
WO2024218650A1 (en) Lilrb1 and lilrb2 antibodies and methods of use thereof
CN117715932A (zh) 一种cdc平台抗体
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom